Glecaprevir + Pibrentasvir OverviewGlecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in Europe) is a combination drug containing glecaprevir (100mg) and pibrentasvir (40mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C. In Europe, it was also approved in August 2017 for the same indication. Contents 1 Medical uses 2 Side effects 3 Clinical trials 4 Development 5 References Medical uses Mavyr...
Read more Glecaprevir + Pibrentasvir Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glecaprevir/pibrentasvir
Recent Glecaprevir + Pibrentasvir Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Glecaprevir + Pibrentasvir
- Tablet: 100mg + 40mg